Dr. Stephanos Ioannidis obtained his bachelor of science at King's College London in chemistry and biochemistry. He then moved to the Imperial College London where he received his PhD in organic chemistry under the supervision of Professor Donald Craig. Following his PhD work, Dr. Stephanos joined the laboratory of Professor Yoshito Kishi at Harvard University as post-doctoral fellow. After completing his post-doctoral studies, he joined AstraZeneca in Waltham, MA. At AstraZeneca, he led several drug discovery teams from target validation stages to the clinic.
In 2013, after more than 11 years of a successful career at AstraZeneca, Dr. Stephanos moved to FORMA Therapeutics in Watertown, MA. At FORMA Therapeutics, Dr. Ioannidis leads the protein homeostasis area where one of his responsibilities includes the discovery of novel small molecules of deubiquitinase (type of enzyme; DUB) enzymes. Other responsibilities include leadership of early discovery and, more recentl,y leading DUB projects related to Parkinson's disease.